Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
NEW YORK Publicis Groupe’s Saatchi & Saatchi, already eliminated in the review for creative chores on Tylenol’s estimated $115 million account, is losing ad duties on the three other Johnson & Johnson brands it handles: Pepcid, Mylanta and St. Joseph aspirin, an agency representative confirmed. Spending on those brands is estimated at $75 million.
It’s unclear where the brands will land. But under one scenario, they could shift wholesale to another roster shop, such as Interpublic Group’s Alchemy in New York, sources said.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in